This work was supported by the grants from the National Natural Science Foundation of China (NSFC) (No 30772588 and No 30721005), the National Science & Technology Major Project"Key New Drug Creation and Manufacturing Program"of China (No 2009ZX09301-001) and the Science and Technology Commission of Shanghai Municipality (STCSM) (No 08DZ1980200).
The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made P...